VKTX

Viking Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$27.58

Price (1 Year)

$38.86 $24.4

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %5.8 / %30
Non-compliant assets / Total market cap %19.4 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Website

Analysis (Turkish): VKTX Hissesi Caiz mi, Helal mi? Viking Therapeutics, Inc. Katılım Analizi